West Pharmaceutical Services Management
Management criteria checks 4/4
West Pharmaceutical Services' CEO is Eric Green, appointed in Apr 2015, has a tenure of 9.67 years. total yearly compensation is $9.40M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $55.64M. The average tenure of the management team and the board of directors is 4.5 years and 8.9 years respectively.
Key information
Eric Green
Chief executive officer
US$9.4m
Total compensation
| CEO salary percentage | 12.1% |
| CEO tenure | 9.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.5yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08West Pharmaceutical Services: The Run Might Be Over
Oct 18West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08West Pharmaceutical: Hard To Justify The Price
May 26West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
| Sep 30 2019 | n/a | n/a | US$230m |
| Jun 30 2019 | n/a | n/a | US$229m |
| Mar 31 2019 | n/a | n/a | US$219m |
| Dec 31 2018 | US$5m | US$880k | US$207m |
| Sep 30 2018 | n/a | n/a | US$155m |
| Jun 30 2018 | n/a | n/a | US$151m |
| Mar 31 2018 | n/a | n/a | US$133m |
| Dec 31 2017 | US$5m | US$824k | US$151m |
Compensation vs Market: Eric's total compensation ($USD9.40M) is about average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Green (54 yo)
9.7yrs
Tenure
US$9,395,896
Compensation
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.7yrs | US$9.40m | 0.23% $ 55.6m | |
| Senior VP & CFO | 6.5yrs | US$3.64m | 0.0095% $ 2.3m | |
| Senior VP & CTO | 4yrs | US$1.67m | 0.0043% $ 1.0m | |
| Senior VP | 4yrs | US$1.49m | 0.0019% $ 451.2k | |
| Senior VP & Chief Commercial Officer | 5.1yrs | US$1.53m | 0.0067% $ 1.6m | |
| VP, Chief Accounting Officer & Corporate Controller | 5.2yrs | no data | 0.0018% $ 434.4k | |
| Head of Investor Relations | no data | no data | no data | |
| Vice President of Global Communications | no data | no data | no data | |
| Senior VP of Strategy & Corporate Development | 1.1yrs | no data | no data | |
| Chief Human Resources Officer & Senior VP | 9.2yrs | US$1.14m | 0.0090% $ 2.2m | |
| Senior VP and Chief Quality & Regulatory Officer | 2.6yrs | no data | no data | |
| President of Contract Manufacturing | less than a year | no data | no data |
4.5yrs
Average Tenure
54yo
Average Age
Experienced Management: WST's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.6yrs | US$9.40m | 0.23% $ 55.6m | |
| Independent Director | 10.8yrs | US$359.35k | 0.024% $ 5.7m | |
| Independent Director | 4.8yrs | US$330.66k | 0.0034% $ 806.4k | |
| Independent Director | 17.2yrs | US$390.35k | 0.059% $ 14.3m | |
| Director | no data | no data | 0.00059% $ 141.6k | |
| Independent Director | 13.8yrs | US$378.23k | 0.056% $ 13.5m | |
| Independent Director | 13.8yrs | US$377.01k | 0.059% $ 14.2m | |
| Lead Independent Director | 8.3yrs | US$367.44k | 0.012% $ 2.9m | |
| Independent Director | 2.4yrs | US$331.46k | 0.0015% $ 355.2k | |
| Independent Director | 12.8yrs | US$362.83k | 0.040% $ 9.6m | |
| Independent Director | 7.5yrs | US$333.45k | no data | |
| Independent Director | 3.3yrs | US$321.43k | 0.00087% $ 208.8k |
8.9yrs
Average Tenure
64yo
Average Age
Experienced Board: WST's board of directors are considered experienced (8.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Lawrence Marsh | Barclays |
| Michael Ryskin | BofA Global Research |